EP
TWST icon

Edgestream Partners’s Twist Bioscience TWST Stock Holding History

Edgestream Partners’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,061
Closed -$242K – 1041
2024
Q1 		$242K Buy
+7,061
New +$255K 0.01% 757

Other funds holding TWST

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgestream Partners's TWST Position: Q2 2024 in Review

Edgestream Partners sold out of Twist Bioscience (TWST) in Q2 2024, closing a stake of 7,061 shares — an estimated $242K sold.

Edgestream Partners first reported a position in TWST in Q1 2024 and held it in 1 quarter. The position peaked at $242K in Q1 2024. 262 funds tracked by Wall St. Rank hold TWST as of Q2 2024.

  • Edgestream Partners reported no remaining Twist Bioscience position as of Q2 2024 after selling out during the quarter.
  • Edgestream Partners sold 7,061 Twist Bioscience shares in Q2 2024, an estimated $242K.
  • Edgestream Partners first reported a position in Twist Bioscience in Q1 2024 and held it in 1 quarter.
  • Edgestream Partners's Twist Bioscience position peaked at $242K in Q1 2024.
  • 262 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2024.

Based on Edgestream Partners's 13F filing for Q2 2024, filed 9 Aug 2024.